Childhood Medulloblastoma: Old Challenges, New Perspectives
Attinà G, Ariano A, Triarico S, Capozza MA, Maurizi P, Mastrangelo S and Ruggiero APediatric Oncology Unit, Fondazione Policlinico Universitario A.Gemelli IRCCS, Universita’ Cattolica Sacro Cuore, Rome, Italy.
Corresponding Author E-mail: antonio.ruggiero@unicatt.it
Abstract: Medulloblastoma (MB) is the first primary central nervous system cancer of infancy. During the last thirty years, there has been an evolution of its treatment: although chemotherapy and radiotherapy have improved the prognosis, surgery remains a determinant key-factor for therapeutic outcome. The search of an effective adjuvant treatment along with a reduced toxicity is difficult. Following treatment with surgery, chemotherapy and radiotherapy, the prognosis for infants and young children with MB is still unfavourable and burdened by an high risk of neurocognitive deficits. The biological features of MB are not fully characterized, but now there are important directions for research. Clinical and molecular prognostic markers can be used to create a disease risk classification. In our review we resume the main features of MB, including clinical, histopathologic and molecular aspects and discuss on the therapeutic options for its treatment.
Keywords: Children; Histopathology; Infants, Moleculars; Medulloblastoma; Marker; Radiotherapy; Risk groups; treatment, Back to TOC